53
|
Guillot-Delost M, Guilleré L, Berger F, Ventre A, Michea P, Sirven P, Pattarini L, Scholer-Dahirel A, Kebir FZ, Huerre M, Chouchane-Mlik O, Lappartient E, Rodriguez J, Jouffroy T, Klijanienko J, Nicolas A, Sastre-Garau X, Honorio S, Mosseri V, Le Peltier N, Sablin MP, Le Tourneau C, Tartour É, Badoual C, Soumelis V. Ligand-receptor dissociated expression explains high TSLP without prognostic impact in human primary head and neck squamous cell carcinoma. Oncoimmunology 2016; 5:e1179414. [PMID: 27622034 DOI: 10.1080/2162402x.2016.1179414] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 04/08/2016] [Accepted: 04/11/2016] [Indexed: 01/04/2023] Open
Abstract
Thymic stromal lymphopoietin (TSLP) is an interleukin (IL)-7-like cytokine expressed by epithelial cells during allergic inflammation, and activating dendritic cells (DC). Its expression and functional role in cancer remain controversial. We conducted retrospective (n = 89), and prospective studies including patients with untreated primary head and neck squamous cell carcinoma (HNSCC). We found that TSLP was overexpressed by HNSCC tumor cells, and associated with a highly differentiated status. However, no significant difference in overall and recurrence-free survival was found between patients bearing a tumor with high and low TSLP levels, respectively. Surprisingly, there was no significant association between the levels of TSLP expression, and the number of tumor-infiltrating mature DCLAMP(+) DC. In order to explain the apparent lack of TSLP-induced DC activation, we performed phenotypic and functional experiments on freshly resected tumors. Tumor-infiltrating immune cells, including DC, did not express the TSLP receptor heterodimer (TSLPR chain, IL-7Ralpha chain). Furthermore, freshly sorted blood CD11c(+) DC from healthy donors cultured with tumor-conditioned supernatant exhibited an activated profile, but this was not affected by an anti-TSLP blocking antibody, suggesting a DC activation pathway independent of tumor-derived TSLP. Overall, our results demonstrate that TSLP is overexpressed in HNSCC but its function is hampered by the lack of TSLPR-expressing cells in the tumor microenvironment. Such a dissociated ligand-receptor expression may impact intercellular communication in other immune activation pathways, and tumor types.
Collapse
Affiliation(s)
- Maude Guillot-Delost
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| | - Lia Guilleré
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| | | | - Aurore Ventre
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| | - Paula Michea
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| | - Philémon Sirven
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| | - Lucia Pattarini
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| | - Alix Scholer-Dahirel
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| | | | - Michel Huerre
- Institut Curie, Service de pathologie , Paris, France
| | | | | | | | | | | | - André Nicolas
- Institut Curie, Service de pathologie , Paris, France
| | | | - Sofia Honorio
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| | | | | | | | | | - Éric Tartour
- Inserm U970 Immunothérapie et traitement anti-angiogénique en cancérologie, Université Paris Descartes, PARCC/HEGP , Paris, France
| | - Cécile Badoual
- Inserm U970 Immunothérapie et traitement anti-angiogénique en cancérologie, Université Paris Descartes, PARCC/HEGP , Paris, France
| | - Vassili Soumelis
- Institut Curie, Laboratoire d'Immunologie Clinique, Paris, France; Institut National de la Santé et de la Recherche Médicale, U932, Institut Curie, Paris, France; Inserm Center of Clinical Investigation, CIC IGR Curie 1428, Paris, France
| |
Collapse
|
54
|
Ghirelli C, Sadacca B, Reyal F, Zollinger R, Michea P, Sirven P, Pattarini L, Martínez-Cingolani C, Guillot-Delost M, Nicolas A, Scholer-Dahirel A, Soumelis V. No evidence for TSLP pathway activity in human breast cancer. Oncoimmunology 2016; 5:e1178438. [PMID: 27622057 DOI: 10.1080/2162402x.2016.1178438] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/22/2016] [Revised: 04/08/2016] [Accepted: 04/08/2016] [Indexed: 01/07/2023] Open
Abstract
Thymic stromal lymphopoietin (TSLP) is an epithelial cell-derived cytokine that primes dendritic cells for Th2 induction. It has been implicated in different types of allergic diseases. Recent work suggested that TSLP could play an important role in the tumor microenvironment and influence tumor progression, in particular in breast cancer. In this study we systematically assessed the production of TSLP at the mRNA and protein levels in several human breast cancer cell lines, large-scale public transcriptomics data sets, and primary human breast tumors. We found that TSLP production was marginal, and concerned less than 10% of the tumors, with very low mRNA and protein levels. In most cases TSLP was undetectable and found to be expressed at lower levels in breast cancer as compared to normal breast tissue. Last, we could not detect any functional TSLP receptor (TSLPR) expression neither on hematopoietic cells nor on stromal cells within the primary tumor microenvironment. We conclude that TSLP-TSLPR pathway activity is not significantly detected within human breast cancer. Taken together, these observations do not support TSLP targeting in breast cancer.
Collapse
Affiliation(s)
- Cristina Ghirelli
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| | - Benjamin Sadacca
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut Curie, Paris, France; Statistics and Genome team of the Laboratoire de Mathématiques et Modélisation d'Évry, University of Évry val d'Essonne/UMR CNRS 8071/USC INRA, Evry, France
| | - Fabien Reyal
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France; Residual Tumor & Response to Treatment Laboratory, RT2Lab, Translational Research Department, Institut Curie, Paris, France; Department of Surgery, Institut Curie, Paris, France
| | - Raphaël Zollinger
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| | - Paula Michea
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| | - Philémon Sirven
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| | - Lucia Pattarini
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| | - Carolina Martínez-Cingolani
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| | - Maude Guillot-Delost
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| | - André Nicolas
- Platform of Investigative Pathology of Biopathology Department, Curie Institute , Paris, France
| | - Alix Scholer-Dahirel
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| | - Vassili Soumelis
- U932 Immunity and Cancer, INSERM, Institut Curie, Paris, France; Department of Immunology, Institut Curie, Paris, France; Inserm Center of Clinical Investigations, CIC IGR Curie, Paris, France
| |
Collapse
|